CN110437236B - 一种吲哚-1,2-并1,4-苯并二氮杂卓类化合物及其合成方法 - Google Patents
一种吲哚-1,2-并1,4-苯并二氮杂卓类化合物及其合成方法 Download PDFInfo
- Publication number
- CN110437236B CN110437236B CN201910801207.1A CN201910801207A CN110437236B CN 110437236 B CN110437236 B CN 110437236B CN 201910801207 A CN201910801207 A CN 201910801207A CN 110437236 B CN110437236 B CN 110437236B
- Authority
- CN
- China
- Prior art keywords
- reaction
- indole
- cdcl
- benzodiazepine
- nmr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- -1 1, 4-benzodiazepine compound Chemical class 0.000 title claims abstract description 22
- GSODHWYZNHBOHR-UHFFFAOYSA-N 4,5,6,7-tetrahydro-1h-diazepine Chemical compound C1CCC=NNC1 GSODHWYZNHBOHR-UHFFFAOYSA-N 0.000 title claims abstract description 17
- 238000010189 synthetic method Methods 0.000 title claims description 4
- 238000006243 chemical reaction Methods 0.000 claims abstract description 86
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 18
- 239000001257 hydrogen Substances 0.000 claims abstract description 18
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims abstract description 11
- 238000007363 ring formation reaction Methods 0.000 claims abstract description 11
- 230000005012 migration Effects 0.000 claims abstract description 10
- 238000013508 migration Methods 0.000 claims abstract description 10
- GUJAGMICFDYKNR-UHFFFAOYSA-N 1,4-benzodiazepine Chemical class N1C=CN=CC2=CC=CC=C12 GUJAGMICFDYKNR-UHFFFAOYSA-N 0.000 claims abstract description 7
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 6
- 238000001308 synthesis method Methods 0.000 claims abstract description 5
- 230000000977 initiatory effect Effects 0.000 claims abstract description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 27
- 239000000126 substance Substances 0.000 claims description 26
- 239000000758 substrate Substances 0.000 claims description 26
- 239000000654 additive Substances 0.000 claims description 12
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 11
- SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 11
- 239000002904 solvent Substances 0.000 claims description 10
- DVWQNBIUTWDZMW-UHFFFAOYSA-N 1-naphthalen-1-ylnaphthalen-2-ol Chemical compound C1=CC=C2C(C3=C4C=CC=CC4=CC=C3O)=CC=CC2=C1 DVWQNBIUTWDZMW-UHFFFAOYSA-N 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 229910019142 PO4 Inorganic materials 0.000 claims description 9
- 230000000996 additive effect Effects 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 9
- 239000010452 phosphate Substances 0.000 claims description 9
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims description 8
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 7
- 239000003054 catalyst Substances 0.000 claims description 7
- 230000002194 synthesizing effect Effects 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 239000002808 molecular sieve Substances 0.000 claims description 6
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 claims description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- HZXJVDYQRYYYOR-UHFFFAOYSA-K scandium(iii) trifluoromethanesulfonate Chemical compound [Sc+3].[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F HZXJVDYQRYYYOR-UHFFFAOYSA-K 0.000 claims description 4
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 claims description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 claims description 4
- 230000002378 acidificating effect Effects 0.000 claims description 3
- 239000007809 chemical reaction catalyst Substances 0.000 claims description 3
- 150000002475 indoles Chemical class 0.000 claims description 3
- 230000000269 nucleophilic effect Effects 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 claims description 2
- ZXMGHDIOOHOAAE-UHFFFAOYSA-N 1,1,1-trifluoro-n-(trifluoromethylsulfonyl)methanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)NS(=O)(=O)C(F)(F)F ZXMGHDIOOHOAAE-UHFFFAOYSA-N 0.000 claims description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims description 2
- 229920000858 Cyclodextrin Polymers 0.000 claims description 2
- 239000001116 FEMA 4028 Substances 0.000 claims description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- 238000004458 analytical method Methods 0.000 claims description 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 2
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 2
- 229960004853 betadex Drugs 0.000 claims description 2
- 238000003818 flash chromatography Methods 0.000 claims description 2
- 230000007246 mechanism Effects 0.000 claims description 2
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000000741 silica gel Substances 0.000 claims description 2
- 229910002027 silica gel Inorganic materials 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- 238000004809 thin layer chromatography Methods 0.000 claims description 2
- JKNHZOAONLKYQL-UHFFFAOYSA-K tribromoindigane Chemical compound Br[In](Br)Br JKNHZOAONLKYQL-UHFFFAOYSA-K 0.000 claims description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 claims description 2
- 239000000376 reactant Substances 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 abstract description 5
- FXWFZIRWWNPPOV-UHFFFAOYSA-N 2-aminobenzaldehyde Chemical class NC1=CC=CC=C1C=O FXWFZIRWWNPPOV-UHFFFAOYSA-N 0.000 abstract description 2
- 238000003547 Friedel-Crafts alkylation reaction Methods 0.000 abstract description 2
- 238000007126 N-alkylation reaction Methods 0.000 abstract description 2
- 150000001299 aldehydes Chemical class 0.000 abstract description 2
- 239000006227 byproduct Substances 0.000 abstract description 2
- 238000010523 cascade reaction Methods 0.000 abstract description 2
- 150000001923 cyclic compounds Chemical class 0.000 abstract description 2
- 230000018044 dehydration Effects 0.000 abstract description 2
- 238000006297 dehydration reaction Methods 0.000 abstract description 2
- 238000007871 hydride transfer reaction Methods 0.000 abstract description 2
- 230000008569 process Effects 0.000 abstract description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 82
- ZFRKQXVRDFCRJG-UHFFFAOYSA-N skatole Chemical compound C1=CC=C2C(C)=CNC2=C1 ZFRKQXVRDFCRJG-UHFFFAOYSA-N 0.000 description 40
- 239000000047 product Substances 0.000 description 28
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 20
- 238000005160 1H NMR spectroscopy Methods 0.000 description 20
- 238000002955 isolation Methods 0.000 description 20
- QJHUKBIDTDKVSL-UHFFFAOYSA-N 2-pyrrolidin-1-ylbenzaldehyde Chemical compound O=CC1=CC=CC=C1N1CCCC1 QJHUKBIDTDKVSL-UHFFFAOYSA-N 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 3
- ZFDQHODXVZRPFG-UHFFFAOYSA-N 3-propan-2-yl-1h-indole Chemical compound C1=CC=C2C(C(C)C)=CNC2=C1 ZFDQHODXVZRPFG-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 150000002466 imines Chemical class 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- DQFQCHIDRBIESA-UHFFFAOYSA-N 1-benzazepine Chemical compound N1C=CC=CC2=CC=CC=C12 DQFQCHIDRBIESA-UHFFFAOYSA-N 0.000 description 1
- 238000004293 19F NMR spectroscopy Methods 0.000 description 1
- SQDFWBUESZGRBR-UHFFFAOYSA-N 1h-azepine;1h-indole Chemical group N1C=CC=CC=C1.C1=CC=C2NC=CC2=C1 SQDFWBUESZGRBR-UHFFFAOYSA-N 0.000 description 1
- BGRDUEIRMDDGTJ-UHFFFAOYSA-N 2-(3,4-dihydro-1H-isoquinolin-2-yl)-4-methoxybenzaldehyde Chemical compound COc1ccc(C=O)c(c1)N1CCc2ccccc2C1 BGRDUEIRMDDGTJ-UHFFFAOYSA-N 0.000 description 1
- PSCQWUVJZIUWGY-UHFFFAOYSA-N 2-(3,4-dihydro-1h-isoquinolin-2-yl)benzaldehyde Chemical compound O=CC1=CC=CC=C1N1CC2=CC=CC=C2CC1 PSCQWUVJZIUWGY-UHFFFAOYSA-N 0.000 description 1
- GCJAQWVHRQAPGF-UHFFFAOYSA-N 2-fluoro-6-pyrrolidin-1-ylbenzaldehyde Chemical compound FC1=CC=CC(N2CCCC2)=C1C=O GCJAQWVHRQAPGF-UHFFFAOYSA-N 0.000 description 1
- SMABIQIPGVQEEX-UHFFFAOYSA-N 2-piperidin-1-ylbenzaldehyde Chemical compound O=CC1=CC=CC=C1N1CCCCC1 SMABIQIPGVQEEX-UHFFFAOYSA-N 0.000 description 1
- UFTZMZPCTMQJLZ-UHFFFAOYSA-N 2-pyrrolidin-1-yl-4-(trifluoromethyl)benzaldehyde Chemical compound FC(F)(F)C1=CC=C(C=O)C(N2CCCC2)=C1 UFTZMZPCTMQJLZ-UHFFFAOYSA-N 0.000 description 1
- OAQSYTBPFVCXHW-UHFFFAOYSA-N 2-pyrrolidin-2-ylbenzaldehyde Chemical compound O=Cc1ccccc1C1CCCN1 OAQSYTBPFVCXHW-UHFFFAOYSA-N 0.000 description 1
- REQGRJQLONTTLF-UHFFFAOYSA-N 3,6-dimethyl-1h-indole Chemical compound CC1=CC=C2C(C)=CNC2=C1 REQGRJQLONTTLF-UHFFFAOYSA-N 0.000 description 1
- OEAIFMBNNQTVPO-UHFFFAOYSA-N 3-chloro-2-pyrrolidin-1-ylbenzaldehyde Chemical compound ClC1=CC=CC(C=O)=C1N1CCCC1 OEAIFMBNNQTVPO-UHFFFAOYSA-N 0.000 description 1
- ZIMDFNSSSFQCJX-UHFFFAOYSA-N 3-methyl-6-phenylmethoxy-1h-indole Chemical compound C=1C=C2C(C)=CNC2=CC=1OCC1=CC=CC=C1 ZIMDFNSSSFQCJX-UHFFFAOYSA-N 0.000 description 1
- UZVCTORVMMDVAN-UHFFFAOYSA-N 4-bromo-2-pyrrolidin-1-ylbenzaldehyde Chemical compound BrC1=CC=C(C=O)C(N2CCCC2)=C1 UZVCTORVMMDVAN-UHFFFAOYSA-N 0.000 description 1
- VRWURYOVNOYKFE-UHFFFAOYSA-N 4-methyl-2-pyrrolidin-1-ylbenzaldehyde Chemical compound CC1=CC=C(C=O)C(N2CCCC2)=C1 VRWURYOVNOYKFE-UHFFFAOYSA-N 0.000 description 1
- ZXWDBZZRCBUVNZ-UHFFFAOYSA-N 5-bromo-2-(3,4-dihydro-1H-isoquinolin-2-yl)benzaldehyde Chemical compound BrC=1C=CC(=C(C=O)C=1)N1CC2=CC=CC=C2CC1 ZXWDBZZRCBUVNZ-UHFFFAOYSA-N 0.000 description 1
- LJFVGMUBSYLFLX-UHFFFAOYSA-N 6-bromo-3-methyl-1h-indole Chemical compound BrC1=CC=C2C(C)=CNC2=C1 LJFVGMUBSYLFLX-UHFFFAOYSA-N 0.000 description 1
- SRCFQMOGKWYADE-UHFFFAOYSA-N 6-chloro-3-methyl-1h-indole Chemical compound ClC1=CC=C2C(C)=CNC2=C1 SRCFQMOGKWYADE-UHFFFAOYSA-N 0.000 description 1
- LSMGVUHULSBVAW-UHFFFAOYSA-N 6-methoxy-3-methyl-1h-indole Chemical compound COC1=CC=C2C(C)=CNC2=C1 LSMGVUHULSBVAW-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 239000000852 hydrogen donor Substances 0.000 description 1
- 150000002478 indolizines Chemical class 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960003955 mianserin Drugs 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
- 238000006276 transfer reaction Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Indole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
本发明公开了一种吲哚‑1,2‑并1,4‑苯二氮杂卓类化合物的合成方法,属于化学合成技术领域。本发明的吲哚‑1,2‑并1,4‑苯二氮杂卓类化合物是通过串联N‑烷基化、脱水、[1,5]‑氢化物转移以及Friedel‑Crafts烷基化等过程,引发3‑烷基吲哚与邻氨基苯甲醛的氧化还原‑中性[5+2]环化反应。本方法通过氢迁移/环化串联反应快速构建新型含吲哚骨架环状化合物,醛自身环化反应较少,并通过氢迁移活化惰性C(sp3)‑H键,具有简洁、绿色、高效等特点,条件简单,反应快捷,生成的副产物为水,绿色环保。
Description
技术领域
本发明属于化学合成技术领域,具体涉及一种吲哚-1,2-并1,4-苯并二氮杂卓类化合物的合成方法。
背景技术
氮卓类骨架是重要的生物活性子,这类骨架化合物经常用于杀虫、除草、杀菌、抗寄生虫及抗肿瘤药物中。
然而,现有的合成氮杂环的氢迁移反应仍然存在一些亟待解决的科学问题:氢供体和氢受体往往需要预先合成,操作复杂;反应模式相对单一,大部分为氢迁移/环化模式;通过氢迁移反应合成七元氮杂环的研究较少。
吲哚并氮卓类骨架也是许多天然产物和药物的活性组成部分,因此探索以吲哚骨架为起始原料构建多元并环的方法尤为重要且具有挑战性。
现有技术表明,以吲哚骨架为反应底物合成吲哚并七元杂氮环类化合物需要经过4-7步中间反应过程,操作复杂;而且反应模式相对单一,大部分为氢迁移/环化模式。
吲哚作为一种常见的亲核试剂,其不同化学位置的反应性存在差异。2018年,Wang课题组报道了底物调控的氢迁移反应以合成多环吲哚和吲哚并氮卓类化合物,通过更换不同反应条件,可获得吲哚3-位关环产物(Chemical Communications,2018,54(57):7928-7931.)。
通常来说吲哚3-位亲核性最强,其次是1-位及2-位。目前对于吲哚的反应研究主要集中在3-位,而对于吲哚2-位及1-位的反应研究较少。
发明内容
针对现有技术中存在的问题,本发明的目的在于提供一种吲哚-1,2-并1,4-苯二氮杂卓类化合物的及其合成方法,通过级联N-烷基化、脱水、[1,5]-氢化物转移以及Friedel-Crafts烷基化序列等过程,引发3-烷基吲哚与邻氨基苯甲醛的氧化还原-中性[5+2]环化反应,最终合成吲哚-1,2-并1,4-苯二氮杂卓类化合物。
吲哚-1,2-并1,4-苯二氮杂卓类化合物的结构如式Ⅰ所示:
其中,
式Ⅰ中虚线表示含环骨架,所述含环骨架选自五元环、五元并环、六元环、六元并环、七元环中任意一种;
R1选自C1-C3烷基、甲氧基、苄氧基、卤素、氢中任意一种;
R2选自C1-C3烷基、异丙基、吲哚亚甲基中任意一种;
R3选自C1-C3烷基、卤素、三氟甲基、氢中任意一种。
一种吲哚-1,2-并1,4-苯二氮杂卓类化合物的合成方法,化学反应式如下:
其中,
虚线表示含环骨架,所述含环骨架选自五元环、五元并环、六元环、六元并环、七元环中任意一种;
R1选自C1-C3烷基、甲氧基、苄氧基、卤素、氢中任意一种;
R2选自C1-C3烷基、异丙基、吲哚亚甲基中任意一种;
R3选自C1-C3烷基、卤素、三氟甲基、氢中任意一种;
3-烷基吲哚类化合物1-位氮对邻氨基苯甲醛类化合物羰基亲核进攻,生成的醇在酸性条件下脱水生成碳正离子,随后碳正离子引发[1,5]-氢迁移,最后亚胺正离子与3-烷基吲哚类化合物2-位进行环化反应最终得到目标产物。
在上述方案的基础上,所述催化剂为联萘酚磷酸酯、三氟甲烷磺酸、三氟甲磺酰亚胺、甲烷磺酸、樟脑磺酸、三氟乙酸、硫酸、三氟甲磺酸钪、三溴化铟或三氟化硼乙醚;
优选地,选用联萘酚磷酸酯做催化剂。
在上述方案的基础上,所述溶剂为二氯甲烷、四氯化碳、甲苯、1,2-二氯乙烷、乙腈、四氢呋喃、乙醇或二甲基亚砜;
优选地,选用二氯甲烷做溶剂。
在上述方案的基础上,所述反应温度为80℃。
在上述方案的基础上,在合成反应中添加反应添加物以提高产率;
优选地,选用无水硫酸钠做反应添加物。
在上述方案的基础上,所述无水硫酸钠的用量为0.2-3当量;
优选地,无水硫酸钠的用量为1.2当量。
在上述方案的基础上,所述吲哚-1,2-并1,4-苯二氮杂卓类化合物的合成方法,具体步骤如下:
由3-烷基吲哚类化合物与邻氨基苯甲醛类化合物作为反应底物,以20mol%联萘酚磷酸酯作为反应催化剂,以二氯甲烷作溶剂,以1.2当量无水硫酸钠作反应添加物,在80℃条件下反应24h;在通过薄层色谱点板分析表明反应完成后,将混合物真空浓缩,并通过硅胶快速柱色谱法直接纯化残余物,即得。
反应机理是:3-甲基吲哚1-位氮对2-吡咯烷基苯甲醛羰基亲核进攻,生成的醇在酸性条件下脱水生成碳正离子,随后碳正离子引发[1,5]-氢迁移,最后亚胺正离子与3-甲基吲哚2-位进行环化反应最终得到目标产物。
本发明有益效果:本发明能够实现通过氢迁移/环化串联反应快速构建新型含吲哚骨架环状化合物;吲哚并七元氮杂环产物与抗抑郁药物米安色林相似,都具有苯并氮杂七元环结构且包含吲哚骨架,具有相似结构的化合物一般具有类似活性,因此,本发明制备的吲哚-1,2-并1,4-苯二氮杂卓类化合物具有潜在生物生理活性,例如降血压、抗过敏、抗抑郁等;醛自身环化反应较少;该反应通过氢迁移活化惰性C(sp3)-H键,具有简洁、绿色、高效等特点,条件简单,反应快捷,生成的副产物为水,绿色环保。
附图说明
图1为本发明实施例4产物的1H NMR谱;
图2为本发明实施例4产物的13C NMR谱;
图3为本发明实施例4产物的NOE二维谱。
具体实施方式
在本发明中所使用的术语,除非有另外说明,一般具有本领域普通技术人员通常理解的含义。
下面结合具体实施例,并参照数据进一步详细的描述本发明。以下实施例只是为了举例说明本发明,而非以任何方式限制本发明的范围。
实施例1
表1
注:反应条件为:3-甲基吲哚(0.2mmol)和2-吡咯烷基苯甲醛(0.6mmol)作为反应底物在催化剂(0.04mmol)催化下在溶剂(1.0mL)中反应24h,反应温度根据不同实验目的进行设定;产率为GC产率;第17组产率为0,表示反应未进行。
实施例2
以3-甲基吲哚和2-吡咯烷基苯甲醛作为反应底物,固定反应催化剂为联萘酚磷酸酯、溶剂为二氯甲烷,反应温度为80℃,对反应添加物进行筛选。
设定反应各物质固定用量为3-甲基吲哚0.2mmol、2-吡咯烷基苯甲醛0.6mmol、20mol%联萘酚磷酸酯0.04mmol以及二氯甲烷1.0mL,在80℃条件下反应24小时测定产率,对反应添加物进行筛选。结果显示,无水硫酸钠的用量在0.24mmol,即相对于3-甲基吲哚的用量为1.2当量时产率最高,为89%。
表2
注:产率为GC产率;第7-9组Na2SO4的用量分别为0.24mmol、0.04mmol以及0.6mmol;第10-11组Na2SO4的用量都为0.24mmol。
实施例3
为了证明该反应设计的实用性,对底物反应进行放大实验。用3-甲基吲哚(5mmol)和2-吡咯烷基苯甲醛(15.0mmol)在标准条件下反应24小时,结果表明,该克级反应也能以72%的较高收率得到1.04g标准产物3a。
实施例4
以3-甲基吲哚(0.2mmol)和2-吡咯烷基苯甲醛(0.6mmol)作为反应底物,以20mol%联萘酚磷酸酯为催化剂(0.04mmol)、二氯甲烷为溶剂(1.0mL)、1.2当量无水硫酸钠为添加物(0.24mmol),在80℃条件下反应24h。
产物化学式:C20H21N2
分子量:289.17
结构式:
分离产率:79%
1H NMR(500MHz,CDCl3)δ7.49(d,J=7.7Hz,1H),7.40(d,J=8.2Hz,1H),7.16(d,J=7.2Hz,3H),7.05(t,J=7.2Hz,1H),6.80(d,J=8.0Hz,1H),6.75(t,J=7.3Hz,1H),5.40(d,J=14.6Hz,1H),5.23(d,J=14.6Hz,1H),4.90(t,J=7.4Hz,1H),3.37(dd,J=10.8,5.2Hz,2H),2.52–2.45(m,1H),2.44–2.39(m,1H),2.29(s,3H),2.08(ddd,J=14.9,12.9,6.6Hz,2H);13C NMR(125MHz,CDCl3)δ147.36,135.28,134.35,129.05,128.89,128.48,126.83,121.09,119.37,118.64,118.25,115.96,108.39,106.01,60.02,49.56,47.06,31.34,23.03,9.18.
实施例5
反应底物为3-甲基-6-甲氧基吲哚(0.2mmol)和2-吡咯烷基苯甲醛(0.6mmol),其余反应条件与实施例4相同。
产物化学式:C21H23N2O
分子量:319.18
结构式:
分离产率:71%
1H NMR(500MHz,CDCl3)δ7.29(d,J=8.8Hz,1H),7.20-7.13(m,2H),6.94(d,J=2.2Hz,1H),6.85(dd,J=8.8,2.3Hz,1H),6.81(d,J=8.0Hz,1H),6.76(t,J=7.3Hz,1H),5.33(d,J=14.5Hz,1H),5.20(d,J=14.5Hz,1H),4.83(t,J=7.6Hz,1H),3.85(s,3H),3.41–3.31(m,2H),2.52–2.44(m,1H),2.43–2.34(m,1H),2.25(s,3H),2.16–2.00(m,2H);13CNMR(125MHz,CDCl3)δ152.58,146.33,133.99,129.64,127.94,127.70,127.60,126.18,118.51,115.01,110.01,108.06,104.57,99.30,59.17,55.04,48.47,46.15,30.36,21.85,8.17.
实施例6
反应底物为3-甲基-6-苄氧基吲哚(0.2mmol)和2-吡咯烷基苯甲醛(0.6mmol),其余反应条件与实施例4相同。
产物化学式:C27H27N2O
分子量:395.21
结构式:
分离产率:80%
1H NMR(500MHz,CDCl3)δ7.47(d,J=7.4Hz,2H),7.37(t,J=7.5Hz,2H),7.33–7.28(m,2H),7.21–7.14(m,2H),7.03(d,J=2.1Hz,1H),6.93(dd,J=8.8,2.2Hz,1H),6.82(d,J=8.0Hz,1H),6.76(t,J=7.3Hz,1H),5.34(d,J=14.5Hz,1H),5.21(d,J=14.5Hz,1H),5.10(s,2H),4.84(t,J=7.6Hz,1H),3.41–3.34(m,2H),2.52–2.44(m,1H),2.43–2.35(m,1H),2.24(s,3H),2.15–2.02(m,2H);13C NMR(125MHz,CDCl3)δ151.76,146.32,136.84,134.06,129.84,127.96,127.72,127.61,127.44(2C),126.65,126.54(2C),126.14,118.51,115.03,110.77,108.02,104.62,101.14,70.15,59.16,48.48,46.17,30.35,21.86,8.17.
实施例7
反应底物为3-甲基-6-甲基吲哚(0.2mmol)和2-吡咯烷基苯甲醛(0.6mmol),其余反应条件与实施例4相同。
产物化学式:C21H23N2
分子量:303.19
结构式:
分离产率:71%
1H NMR(500MHz,CDCl3)δ7.32–7.27(m,2H),7.21–7.14(m,2H),7.02(d,J=8.3Hz,1H),6.81(d,J=8.0Hz,1H),6.76(t,J=7.4Hz,1H),5.38(d,J=14.5Hz,1H),5.22(d,J=14.5Hz,1H),4.89(t,J=7.6Hz,1H),3.43–3.32(m,2H),2.52–2.37(m,5H),2.27(s,3H),2.18–2.11(m,1H),2.10–2.01(m,1H);13C NMR(125MHz,CDCl3)δ146.33,133.32,132.70,127.90,127.76,127.59,126.72,126.03,121.55,118.33,116.86,114.90,107.01,104.43,59.08,48.48,46.07,30.31,21.92,20.43,8.08.
实施例8
反应底物为3-甲基-6-氯吲哚(0.2mmol)和2-吡咯烷基苯甲醛(0.6mmol),其余反应条件与实施例4相同。
产物化学式:C20H20ClN2
分子量:323.13
结构式:
分离产率:53%
1H NMR(500MHz,CDCl3)δ7.43(d,J=1.9Hz,1H),7.29(d,J=8.7Hz,1H),7.19(td,J=8.0,1.5Hz,1H),7.15(dd,J=7.4,1.2Hz,1H),7.11(dd,J=8.7,2.0Hz,1H),6.82(d,J=7.9Hz,1H),6.77(td,J=7.4,0.8Hz,1H),5.33(d,J=14.5Hz,1H),5.20(d,J=14.5Hz,1H),4.82(t,J=7.6Hz,1H),3.40–3.32(m,2H),2.52–2.43(m,1H),2.41–2.33(m,1H),2.22(s,3H),2.14–2.01(m,2H);13C NMR(125MHz,CDCl3)δ147.29,135.84,133.68,129.52,129.22,128.81,126.76,124.33,121.20,119.69,117.72,116.17,109.40,105.82,60.04,49.56,47.26,31.34,22.92,9.08.
实施例9
反应底物为3-甲基-6-溴吲哚(0.2mmol)和2-吡咯烷基苯甲醛(0.6mmol),其余反应条件与实施例4相同。
产物化学式:C20H20BrN2
分子量:367.08
结构式:
分离产率:34%
1H NMR(500MHz,CDCl3)δ7.59(s,1H),7.28–7.22(m,2H),7.20(t,J=7.7Hz,1H),7.15(d,J=7.4Hz,1H),6.82(d,J=8.1Hz,1H),6.77(t,J=7.4Hz,1H),5.33(d,J=14.5Hz,1H),5.20(d,J=14.5Hz,1H),4.83(t,J=7.6Hz,1H),3.43–3.30(m,2H),2.54–2.43(m,1H),2.42–2.32(m,1H),2.23(s,3H),2.15–2.03(m,2H);13C NMR(125MHz,CDCl3)δ147.28,135.69,133.94,130.18,129.22,128.80,126.77,123.72,120.82,119.72,116.18,111.83,109.85,105.78,60.03,49.55,47.23,31.35,22.89,9.06.
实施例10
反应底物为3-异丙基吲哚(0.2mmol)和2-吡咯烷基苯甲醛(0.6mmol),其余反应条件与实施例4相同。
产物化学式:C22H25N2
分子量:317.20
结构式:
分离产率:43%
1H NMR(500MHz,CDCl3)δ7.67(d,J=8.0Hz,1H),7.45(d,J=8.3Hz,1H),7.27–7.20(m,2H),7.16(t,J=7.6Hz,1H),7.01(t,J=7.4Hz,2H),6.89(t,J=7.4Hz,1H),5.36(d,J=13.7Hz,1H),5.14(d,J=13.7Hz,1H),4.42(dd,J=8.9,7.2Hz,1H),3.38–3.27(m,2H),3.13–3.03(m,1H),2.53–2.39(m,1H),2.15–1.95(m,3H),1.42(d,J=7.1Hz,3H),1.35(d,J=7.1Hz,3H);13C NMR(125MHz,CDCl3)δ147.82,136.18,132.56,131.41,129.00,128.46,126.01,121.78,120.43,120.34,118.29,117.99,117.57,108.88,62.20,49.54,46.51,33.53,26.03,23.26,22.78,21.88.
实施例11
反应底物为3-吲哚亚甲基吲哚(0.2mmol)和2-吡咯烷基苯甲醛(0.6mmol),其余反应条件与实施例4相同。
产物化学式:C28H26N3
分子量:404.21
结构式:
分离产率:71%
1H NMR(500MHz,CDCl3)δ7.68(d,J=7.4Hz,2H),7.45(d,J=8.3Hz,1H),7.40(d,J=7.9Hz,1H),7.28(d,J=8.0Hz,1H),7.21–7.16(m,4H),7.13(td,J=7.5,1.0Hz,1H),6.97(t,J=7.4Hz,1H),6.81–6.71(m,2H),6.40(s,1H),5.47(d,J=14.5Hz,1H),5.27(d,J=14.5Hz,1H),4.97(t,J=7.8Hz,1H),4.22(dd,J=16.8,1.1Hz,1H),4.16(dd,J=16.8,1.1Hz,1H),3.29(t,J=6.8Hz,2H),2.40–2.29(m,2H),2.03–1.86(m,2H);13C NMR(125MHz,CDCl3)δ147.39,136.53,135.64,134.84,129.13,128.93,128.30,127.34,126.83,122.58,121.88,121.20,119.32,119.16,118.93,118.83,118.71,116.42,115.97,111.10,109.32,108.52,60.03,49.63,47.15,31.47,23.11,20.24.
实施例12
反应底物为3-甲基吲哚(0.2mmol)和2-吡咯烷基-4甲基苯甲醛(0.6mmol),其余反应条件与实施例4相同。
产物化学式:C21H23N2
分子量:303.19
结构式:
分离产率:49%
1H NMR(500MHz,CDCl3)δ7.49(d,J=7.8Hz,1H),7.40(d,J=8.2Hz,1H),7.18(t,J=7.6Hz,1H),7.05(t,J=6.6Hz,2H),6.63(s,1H),6.57(d,J=7.6Hz,1H),5.37(d,J=14.5Hz,1H),5.21(d,J=14.5Hz,1H),4.89(t,J=7.6Hz,1H),3.42–3.32(m,2H),2.52–2.45(m,1H),2.43–2.38(m,1H),2.29(s,3H),2.27(s,3H),2.16–2.03(m,2H);13C NMR(125MHz,CDCl3)δ147.20,138.79,135.26,134.38,128.72,128.47,124.13,120.98,120.01,118.53,118.18,116.74,108.37,105.97,60.05,49.51,46.71,31.33,22.99,21.49,9.15.
实施例13
反应底物为3-甲基吲哚(0.2mmol)和2-吡咯烷基-4-三氟甲基苯甲醛(0.6mmol),其余反应条件与实施例4相同。
产物化学式:C21H20F3N2
分子量:357.16
结构式:
分离产率:62%
1H NMR(500MHz,CDCl3)δ7.52(d,J=7.9Hz,1H),7.37(d,J=8.2Hz,1H),7.23–7.17(m,2H),7.07(t,J=7.4Hz,1H),6.90(d,J=7.7Hz,1H),6.85(s,1H),5.55(d,J=15.2Hz,1H),5.23(t,J=7.2Hz,1H),5.16(d,J=15.2Hz,1H),3.46–3.33(m,2H),2.65–2.56(m,1H),2.51–2.43(m,1H),2.35(s,3H),2.22–2.15(m,1H),2.14–2.08(m,1H);13C NMR(125MHz,CDCl3)δ146.25,134.16,132.56,130.21(q,J=31.6Hz),128.27,127.47,126.41,123.16(q,J=270.8Hz),120.55,117.86,117.56,113.40(q,J=3.8Hz),110.47(q,J=3.8Hz),107.16,105.09,57.88,48.61,45.79,29.66,22.50,8.24;19F NMR(470MHz,CDCl3)δ-62.78.
实施例14
反应底物为3-甲基吲哚(0.2mmol)和2-吡咯烷基-6-氟苯甲醛(0.6mmol),其余反应条件与实施例4相同。
产物化学式:C20H20FN2
分子量:307.16
结构式:
分离产率:83%
1H NMR(500MHz,CDCl3)δ7.50(d,J=7.9Hz,1H),7.42(d,J=8.2Hz,1H),7.19(t,J=7.6Hz,1H),7.10–6.99(m,2H),6.44(t,J=9.0Hz,1H),6.40(d,J=8.5Hz,1H),5.49(d,J=15.5Hz,1H),5.40(d,J=15.5Hz,1H),5.14(t,J=7.1Hz,1H),3.36(td,J=8.2,4.8Hz,1H),3.31(dd,J=15.9,7.9Hz,1H),2.56(dq,J=14.2,7.2Hz,1H),2.41(dq,J=13.9,7.0Hz,1H),2.33(s,3H),2.17–2.09(m,1H),2.09–1.99(m,1H);13C NMR(125MHz,CDCl3)δ159.06(d,J=240.5Hz),147.65(d,J=5.6Hz),134.35,133.01,128.08(d,J=11.0Hz),127.28,120.45,117.74,117.29,110.71(d,J=17.4Hz),109.59(d,J=2.4Hz),107.49,104.69,103.92(d,J=23.9Hz),57.70,48.78,36.27(d,J=9.3Hz),29.52,22.48,8.19;19FNMR(470MHz,CDCl3)δ-118.69.
实施例15
反应底物为3-甲基吲哚(0.2mmol)和2-吡咯烷基-3-氯苯甲醛(0.6mmol),其余反应条件与实施例4相同。
产物化学式:C20H20ClN2
分子量:323.13
结构式:
分离产率:77%
1H NMR(500MHz,CDCl3)δ7.45(d,J=7.7Hz,1H),7.41(d,J=8.1Hz,1H),7.25(s,1H),7.21–7.14(m,2H),7.05(t,J=7.1Hz,1H),6.88(t,J=7.3Hz,1H),5.26(d,J=13.8Hz,1H),5.11–4.96(m,2H),4.06–3.92(m,1H),3.31–3.18(m,1H),2.45–2.34(m,1H),2.20(s,3H),2.18–2.11(m,1H),2.11–2.02(m,2H);13C NMR(125MHz,CDCl3)δ142.97,138.03,135.04,133.05,132.55,129.36,127.64,125.79,123.91,120.01,117.76,117.25,107.85,107.15,57.61,49.78,45.49,33.57,23.88,7.42.
实施例16
反应底物为3-甲基吲哚(0.2mmol)和2-吡咯烷基-4-溴苯甲醛(0.6mmol),其余反应条件与实施例4相同。
产物化学式:C20H20BrN2
分子量:367.08
结构式:
分离产率:70%
1H NMR(500MHz,CDCl3)δ7.51(d,J=7.9Hz,1H),7.34(d,J=8.2Hz,1H),7.19(t,J=7.6Hz,1H),7.06(t,J=7.4Hz,1H),6.94(d,J=8.4Hz,1H),6.81–6.72(m,2H),5.42(d,J=15.1Hz,1H),5.13(t,J=7.2Hz,1H),5.06(d,J=15.1Hz,1H),3.38–3.22(m,2H),2.59–2.49(m,1H),2.48–2.39(m,1H),2.33(s,3H),2.20–2.10(m,1H),2.10–2.02(m,1H);13C NMR(125MHz,CDCl3)δ148.26,135.18,133.75,130.19,128.49,123.43,122.74,121.49,120.74,118.82,118.55,118.05,108.28,106.03,59.00,49.66,46.64,30.76,23.52,9.31.
实施例17
反应底物为3-甲基吲哚(0.2mmol)和2-哌啶烷基苯甲醛(0.6mmol),其余反应条件与实施例4相同。
产物化学式:C21H23N2
分子量:303.19
结构式:
分离产率:56%
1H NMR(500MHz,CDCl3)δ7.45–7.37(m,2H),7.21–7.14(m,2H),7.09(d,J=7.1Hz,1H),7.05–6.93(m,2H),6.78(t,J=7.1Hz,1H),5.51(d,J=13.2Hz,1H),4.91(d,J=13.2Hz,1H),4.20(d,J=10.8Hz,1H),3.47(d,J=10.9Hz,1H),3.18(t,J=11.5Hz,1H),2.13(s,3H),2.03–1.92(m,2H),1.88–1.82(m,2H),1.81–1.72(m,1H),1.70–1.61(m,1H);13CNMR(125MHz,CDCl3)δ149.76,135.60,134.80,133.36,127.90,127.78,126.00,120.66,120.00,118.15,117.66,117.18,107.60,107.09,61.42,51.74,45.45,34.45,25.53,24.46,7.52.
实施例18
反应底物为3-甲基吲哚(0.2mmol)和2-(1,2,3,4-四氢异喹啉-2-基)-苯甲醛(0.6mmol),其余反应条件与实施例4相同。
产物化学式:C25H23N2
分子量:351.19
结构式:
分离产率:81%
1H NMR(500MHz,CDCl3)δ7.50(d,J=7.8Hz,1H),7.38(d,J=8.2Hz,1H),7.25–7.19(m,3H),7.18–7.14(m,1H),7.11–7.00(m,4H),6.83–6.70(m,2H),5.87(s,1H),5.18(d,J=14.6Hz,1H),5.06(d,J=14.0Hz,1H),3.94–3.77(m,1H),3.66(ddd,J=12.5,9.1,5.1Hz,1H),3.27–3.13(m,1H),3.04(dt,J=16.4,4.4Hz,1H),2.05(s,3H);13C NMR(125MHz,CDCl3)δ149.31,137.09,136.77,135.26,133.12,130.35,129.15,128.89,128.81,128.32,127.14,126.51,126.27,121.90,120.88(2C),118.93,118.90,111.85,108.97,59.59,50.03,47.25,29.70,8.76.
实施例19
反应底物为3-甲基吲哚(0.2mmol)和2-(1,2,3,4-四氢异喹啉-2-基)-4-甲氧基苯甲醛(0.6mmol),其余反应条件与实施例4相同。
产物化学式:C26H25N2O
分子量:381.20
结构式:
分离产率:64%
1H NMR(500MHz,CDCl3)δ7.50(d,J=7.8Hz,1H),7.36(d,J=8.2Hz,1H),7.22-7.17(m,3H),7.09-7.01(m,2H),6.97(d,J=8.3Hz,1H),6.75(d,J=7.3Hz,1H),6.59(d,J=2.3Hz,1H),6.28(dd,J=8.3,2.4Hz,1H),5.87(s,1H),5.09(d,J=14.6Hz,1H),5.00(d,J=13.7Hz,1H),3.91–3.82(m,1H),3.70(s,3H),3.67–3.60(m,1H),3.23–3.12(m,1H),3.03(dt,J=16.3,4.1Hz,1H),2.05(s,3H);13C NMR(125MHz,CDCl3)δ160.21,150.43,137.00,136.78,135.27,133.11,129.12,129.01,128.77,127.15,126.49,126.30,123.15,121.89,118.93,118.88,111.77,108.98,107.35,105.33,59.48,55.31,50.00,46.64,29.63,8.75.
实施例20
反应底物为3-甲基吲哚(0.2mmol)和2-(1,2,3,4-四氢异喹啉-2-基)-6-氟苯甲醛(0.6mmol),其余反应条件与实施例4相同。
产物化学式:C25H22FN2
分子量:369.18
结构式:
分离产率:78%
1H NMR(500MHz,CDCl3)δ7.51(d,J=7.8Hz,1H),7.44(d,J=8.3Hz,1H),7.24-7.20(M,3H),7.12–7.03(m,3H),6.89-6.74(m,2H),6.52(t,J=8.6Hz,1H),5.94(s,1H),5.37(d,J=15.2Hz,1H),5.18(s,1H),3.83(s,1H),3.72–3.63(m,1H),3.23–3.11(m,1H),3.06(dt,J=9.3,4.4Hz,1H),2.01(s,3H);13C NMR(125MHz,CDCl3)δ159.74(d,J=242.5Hz),151.10(d,J=5.3Hz),137.08,136.34,135.16,132.96,129.11,128.77,128.68,128.57,127.27,126.55,126.40,122.16,119.07,118.81,116.14(d,J=2.6Hz),111.80,109.12,107.32(d,J=23.3Hz),58.90,49.91,37.97(d,J=8.0Hz),29.61,8.60.
实施例21
反应底物为3-甲基吲哚(0.2mmol)和2-(1,2,3,4-四氢异喹啉-2-基)-3-氯苯甲醛(0.6mmol),其余反应条件与实施例4相同。
产物化学式:C25H22ClN2
分子量:385.15
结构式:
分离产率:80%
1H NMR(500MHz,CDCl3)δ7.50(dd,J=7.8,0.5Hz,1H),7.32(d,J=8.2Hz,1H),7.26-7.17(m,4H),7.14-7.08(m,1H),7.08–7.01(m,2H),6.93(d,J=7.7Hz,1H),6.81–6.72(m,1H),6.07(s,1H),5.19–5.11(m,2H),3.67–3.59(m,1H),3.59–3.51(m,1H),3.17(dt,J=16.2,5.6Hz,1H),2.95(dt,J=16.2,5.7Hz,1H),1.92(s,3H);13C NMR(125MHz,CDCl3)δ145.79,136.58,136.27,135.85,134.19,132.91,130.93,130.20,129.34,128.76,127.29,127.14,127.06,126.25,122.72,122.10,119.04,118.97,112.27,108.59,57.13,48.48,47.27,29.32,8.37.
实施例22
反应底物为3-甲基吲哚(0.2mmol)和2-(1,2,3,4-四氢异喹啉-2-基)-5-溴苯甲醛(0.6mmol),其余反应条件与实施例4相同。
产物化学式:C25H22BrN2
分子量:429.10
结构式:
分离产率:62%
1H NMR(500MHz,CDCl3)δ7.53(d,J=7.8Hz,1H),7.37(d,J=8.2Hz,1H),7.27-7.23(m,2H),7.23–7.20(m,2H),7.20(d,J=2.3Hz,1H),7.12–7.04(m,2H),6.92(d,J=8.6Hz,1H),6.74(d,J=7.4Hz,1H),5.85(s,1H),5.12(d,J=14.6Hz,1H),4.99(d,J=13.8Hz,1H),3.91–3.75(m,1H),3.66(ddd,J=12.5,9.3,5.1Hz,1H),3.27–3.13(m,1H),3.04(dt,J=16.4,4.2Hz,1H),2.08(s,3H);13C NMR(125MHz,CDCl3)δ147.28,135.99,135.45,133.95,131.51,130.55,129.77,128.06,127.71,126.18,125.29,121.46,121.10,118.11,117.94,111.83,107.84,58.37,49.04,45.64,28.41,7.64.
实施例23
反应底物为3-甲基吲哚(0.2mmol)和2-(环己亚胺-1-基)-苯甲醛(0.6mmol),其余反应条件与实施例4相同。
产物化学式:C22H25N2
分子量:317.20
结构式:
分离产率:47%
1H NMR(500MHz,CDCl3)δ7.47(d,J=7.8Hz,1H),7.37(d,J=8.2Hz,1H),7.17(t,J=7.6Hz,1H),7.13-7.07(m,2H),7.04(t,J=7.4Hz,1H),6.87(d,J=8.1Hz,1H),6.64(t,J=7.3Hz,1H),5.38(d,J=15.2Hz,1H),5.20(d,J=15.2Hz,1H),4.90(dd,J=10.6,4.9Hz,1H),3.76(ddd,J=14.5,6.7,4.2Hz,1H),3.33(ddd,J=14.5,8.0,3.7Hz,1H),2.39-2.31(m,1H),2.30(s,3H),2.16–2.09(m,1H),2.03-1.94(m,1H),1.94–1.76(m,3H),1.74–1.64(m,2H);13C NMR(125MHz,CDCl3)δ149.13,136.68,136.18,129.47,128.74,128.64,124.88,121.33,118.75,118.71,117.89,116.67,108.61,106.38,58.45,51.94,48.21,36.54,28.85,27.16,26.31,9.15.
以上所述,仅是本发明的较佳实施例而已,并非是对本发明作其它形式的限制,任何熟悉本专业的技术人员可能利用上述揭示的技术内容加以变更或改型为等同变化的等效实施例。但是凡是未脱离本发明技术方案内容,依据本发明的技术实质对以上实施例所作的任何简单修改、等同变化与改型,仍属于本发明技术方案的保护范围。
Claims (7)
1.一种吲哚-1,2-并1,4-苯二氮杂卓类化合物的合成方法,其特征在于,化学反应式如下:
其中,
虚线表示含环骨架,所述含环骨架选自五元环、五元并环、六元环、六元并环、七元环中任意一种;
R1选自C1-C3烷基、甲氧基、苄氧基、卤素、氢中任意一种;
R2选自C1-C3烷基、吲哚亚甲基中任意一种;
R3选自C1-C3烷基、卤素、三氟甲基、氢中任意一种;
反应机理为:
反应物吲哚类化合物1-位氮对邻氨基苯甲醛类化合物羰基亲核进攻,生成的醇在酸性条件下脱水生成碳正离子,随后碳正离子引发[1,5]-氢迁移,最后亚胺正离子与吲哚类化合物2-位进行环化反应最终得到目标产物;
其中使用的催化剂为联萘酚磷酸酯、三氟甲烷磺酸、三氟甲磺酰亚胺、甲烷磺酸、樟脑磺酸、三氟乙酸、硫酸、三氟甲磺酸钪、三溴化铟或三氟化硼乙醚中的一种;
使用的溶剂为二氯甲烷、四氯化碳、甲苯、1,2-二氯乙烷、乙腈、四氢呋喃、乙醇中的一种。
2.根据权利要求1所述吲哚-1,2-并1,4-苯二氮杂卓类化合物的合成方法,其特征在于,所述催化剂为联萘酚磷酸酯。
3.根据权利要求1所述吲哚-1,2-并1,4-苯二氮杂卓类化合物的合成方法,其特征在于,所述溶剂为二氯甲烷。
4.根据权利要求1所述吲哚-1,2-并1,4-苯二氮杂卓类化合物的合成方法,其特征在于,反应温度为80℃。
6.根据权利要求5所述吲哚-1,2-并1,4-苯二氮杂卓类化合物的合成方法,其特征在于,所述反应添加物为无水硫酸钠,所述无水硫酸钠的用量为1.2当量。
7.根据权利要求5所述吲哚-1,2-并1,4-苯二氮杂卓类化合物的合成方法,其特征在于,具体步骤为:
由吲哚类化合物与邻氨基苯甲醛类化合物作为反应底物,以20mol%联萘酚磷酸酯作为反应催化剂,以二氯甲烷作溶剂,以1.2当量无水硫酸钠作反应添加物,在80℃条件下反应24h;在通过薄层色谱点板分析表明反应完成后,将混合物真空浓缩,并通过硅胶快速柱色谱法直接纯化残余物,即得。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910801207.1A CN110437236B (zh) | 2019-08-28 | 2019-08-28 | 一种吲哚-1,2-并1,4-苯并二氮杂卓类化合物及其合成方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910801207.1A CN110437236B (zh) | 2019-08-28 | 2019-08-28 | 一种吲哚-1,2-并1,4-苯并二氮杂卓类化合物及其合成方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110437236A CN110437236A (zh) | 2019-11-12 |
CN110437236B true CN110437236B (zh) | 2020-08-18 |
Family
ID=68438107
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910801207.1A Expired - Fee Related CN110437236B (zh) | 2019-08-28 | 2019-08-28 | 一种吲哚-1,2-并1,4-苯并二氮杂卓类化合物及其合成方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110437236B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113121548A (zh) * | 2021-04-23 | 2021-07-16 | 青岛农业大学 | 一种吲哚并八元中环化合物及其制备方法 |
CN113372352B (zh) * | 2021-06-10 | 2022-08-26 | 青岛农业大学 | 吲哚3,4位并九元中环化合物及其制备方法 |
CN115160330A (zh) * | 2022-08-04 | 2022-10-11 | 青岛农业大学 | 一种氧杂环壬烷并[4,5-b]吲哚类化合物及其制备方法 |
CN115403588A (zh) * | 2022-08-04 | 2022-11-29 | 青岛农业大学 | 氧化吲哚螺二苯并[b,f]氧杂环辛烷类化合物及其制备方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4678784A (en) * | 1984-04-11 | 1987-07-07 | Mcneilab, Inc. | Method for the treatment of LHRH diseases and conditions |
US4737496A (en) * | 1986-10-01 | 1988-04-12 | Ciba-Geigy Corporation | 1,3,4,16b-tetrahydro-2H,10H-indolo[2,1-c]pyrazino-[1,2-a][1,4]benzodiazepines useful as serotonin-2 receptor antagonists |
CN103288828A (zh) * | 2012-02-24 | 2013-09-11 | 中国科学院大连化学物理研究所 | 一种合成手性二氢-6H-吲哚并[2,1-c][1,4]-苯并二氮杂卓的方法 |
-
2019
- 2019-08-28 CN CN201910801207.1A patent/CN110437236B/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN110437236A (zh) | 2019-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110437236B (zh) | 一种吲哚-1,2-并1,4-苯并二氮杂卓类化合物及其合成方法 | |
Zhang et al. | Catalytic asymmetric Povarov reaction of isatin-derived 2-azadienes with 3-vinylindoles | |
CN111978236B (zh) | 一种n-取代-3-吗啉基-4-苯硒基马来酰亚胺化合物的制备方法 | |
CN112028809B (zh) | 一种3-胺基-4-苯硒基马来酰亚胺化合物的制备方法 | |
Gao et al. | Visible-light-induced intramolecular radical cascade of α-bromo-N-benzyl-alkylamides: A new strategy to synthesize tetracyclic N-fused indolo [2, 1-a] isoquinolin-6 (5 H)-ones | |
Yuan et al. | One-Pot synthesis of trifluoromethylated pyrazol-4-yl-pyrrole-2, 5-dione derivatives | |
Borsini et al. | Enantiopure 2-piperidylacetaldehyde as a useful building block in the diversity-oriented synthesis of polycyclic piperidine derivatives | |
CN111978237B (zh) | 一种3-吗啉基-4-芳硒基马来酰亚胺化合物的制备方法 | |
Thirumurugan et al. | InCl3 mediated one-pot synthesis of indol-3-yl pyridine and 2, 2′-bipyridine derivatives through multi-component reaction | |
Mancuso et al. | Palladium-catalyzed carbonylative synthesis of functionalized benzimidazopyrimidinones | |
Guchhait et al. | A highly flexible and efficient Ugi-type multicomponent synthesis of versatile N-fused aminoimidazoles | |
CN105820174B (zh) | 一种多取代噻吩并吲哚衍生物的制备方法 | |
CN108752281B (zh) | 一类巴比妥酸-环己烯螺环化合物及其合成方法 | |
CN111285881B (zh) | 一种噻吩并[3,4-b]吲哚衍生物及其合成方法 | |
CN107868087B (zh) | 一种制备吡咯并吲哚类衍生物的方法 | |
Song et al. | Facile microwave-assisted synthesis of benzimidazole scaffolds via Ugi-type three-component condensation (3CC) reactions | |
CN106892921A (zh) | 一种合成螺茚吡咯并吡啶类化合物的方法 | |
CN114539252A (zh) | 一种2,3-二氢喹啉-4-酮生物活性骨架及其合成方法和应用 | |
CN110483361B (zh) | 一种β-C(sp3)–H官能化和芳构化的吡咯类化合物的合成方法 | |
CN110317170B (zh) | 一种3-菲啶基甲酸丙酯类化合物的绿色合成方法 | |
CN114031613A (zh) | 一种1-(苯并[b]噻吩-7-基)-吲哚衍生物及其合成方法 | |
CN109851599B (zh) | 一种2-氨基苯并呋喃化合物的制备方法 | |
CN108530368B (zh) | 有机碱催化巴比妥酸与二烯二腈加成反应的方法 | |
Szemes et al. | Diastereoselective access to hexahydro-and octahydrofuro [f] indolizines analogues of phenanthro [f] indolizidines alkaloids | |
CN110272417A (zh) | 2-甲基-1,8-萘啶类化合物及其制备方法与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20200818 |